The North America Neutropenia Treatment Market is expected to witness market growth of 5.5% CAGR during the forecast period (2020-2026).
Neutropenia can compromise optimal cancer treatment by increasing, delaying, or even discontinuing the dose of chemotherapy. Such dose modifications are often made during the initial stages of chemotherapy, as neutropenic symptoms frequently occur early in the process of chemotherapy. Treatment response often depends on the delivery of standard chemotherapy doses, and changes in dosing may threaten complete response rates and reduce survival. Caregivers, therefore, face the challenge of maintaining adequate chemotherapy doses while managing neutropenic complications. The evaluation of chemotherapy-induced neutropenia is gaining significance.
Children often experience fever with severe neutropenia. They are given antibiotics to combat infection as they do, so they will need to be Retailized. Repeated use of antibiotics can, however, have side effects such as the production of drug-resistant bacteria, diarrhea or enterocolitis, and inflammation of the intestines. Some antibiotics may have adverse effects on the function of the kidney and liver.
New medications have been designed to support the bone marrow to produce neutrophils and improve the body's protection against infection. These drugs are referred to as granulocyte colony-stimulating factors. They help keep neutrophils in the blood above the level of danger all or most of the time. The shorter the time the neutrophil count is low, the less likely your child will develop a fever or infection. These drugs can reduce the amount and seriousness of infections and reduce Retailizations.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
By Treatment
By Country
Companies Profiled
Unique Offerings from the Publisher
Neutropenia can compromise optimal cancer treatment by increasing, delaying, or even discontinuing the dose of chemotherapy. Such dose modifications are often made during the initial stages of chemotherapy, as neutropenic symptoms frequently occur early in the process of chemotherapy. Treatment response often depends on the delivery of standard chemotherapy doses, and changes in dosing may threaten complete response rates and reduce survival. Caregivers, therefore, face the challenge of maintaining adequate chemotherapy doses while managing neutropenic complications. The evaluation of chemotherapy-induced neutropenia is gaining significance.
Children often experience fever with severe neutropenia. They are given antibiotics to combat infection as they do, so they will need to be Retailized. Repeated use of antibiotics can, however, have side effects such as the production of drug-resistant bacteria, diarrhea or enterocolitis, and inflammation of the intestines. Some antibiotics may have adverse effects on the function of the kidney and liver.
New medications have been designed to support the bone marrow to produce neutrophils and improve the body's protection against infection. These drugs are referred to as granulocyte colony-stimulating factors. They help keep neutrophils in the blood above the level of danger all or most of the time. The shorter the time the neutrophil count is low, the less likely your child will develop a fever or infection. These drugs can reduce the amount and seriousness of infections and reduce Retailizations.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies and
- Online pharmacies
By Treatment
- Colony-stimulating factor
- Antibiotics
- Antifungals and
- Antivirals
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- Amgen, Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- BeyondSpring, Inc.
- Spectrum Pharmaceuticals, Inc.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Mylan N.V.
- Cellerant Therapeutics, Inc.
- Partner Therapeutics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Neutropenia Treatment Market by Distribution channel
Chapter 4. North America Neutropenia Treatment Market by Treatment
Chapter 5. North America Neutropenia Treatment Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Amgen, Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- BeyondSpring, Inc.
- Spectrum Pharmaceuticals, Inc.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Mylan N.V.
- Cellerant Therapeutics, Inc.
- Partner Therapeutics, Inc.
Methodology
LOADING...
